Comparison of The Effects of Thiazolidinediones(TZD), Sodium- Glucose Cotransporter 2 Inhibitors(SGLT2i) Alone and TZD / SGLT2i Combination Therapy on Non-alcoholic Fatty Liver Disease in Type 2 Diabetic Patients With Fatty Liver
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease
- Type2 Diabetes
- Type
- Interventional
- Phase
- Phase 4
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentIntervention Model Description: This study will conduct to evaluate the efficacy of liver fat lowering and safety of empagliflozin 10mg, pioglitazone 15mg alone or in combination with empagliflozin 10mg/pioglitazone 15mg for 6 months.Masking: None (Open Label)Masking Description: open labelPrimary Purpose: Treatment
Participation Requirements
- Age
- Between 19 years and 75 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03646292
- Collaborators
- Not Provided
- Investigators
- Not Provided